Recently, scientists found that some people who suffered from COVID-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signaling proteins. Now, researchers ...

An article published in npj Aging reveals that natural production of auto-antibodies increases with age, and that infection by SARS-CoV-2 can exacerbate production of auto-antibodies relating to ...

Even though COVID-19 manifests as a mild and short-lived disease in most people, some suffer extremely severe symptoms; in the worst cases, these patients die due to complications such as respiratory ...

Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized persons with Covid-19 1 on the basis of the results of the Evaluation of Protease Inhibition for Covid-19 ...

NEW YORK -- For at least 10 months after a COVID-19 infection, your immune system can provide good protection against symptomatic illness the next time around, a new study found, and the risk of ...

Ziyad Al-Aly is chief of research and development at VA St. Louis Health Care System and a clinical epidemiologist at Washington University in St. Louis. Since 2020, the condition known as long ...

Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for ...